Hartmut J. Ehrlich

A Clinical Trial of a Whole-Virus H5N1 Vaccine Derived from Cell Culture

Hartmut J. Ehrlich, Markus Müller, Helen May‐Lin Oh et al. · New England Journal of Medicine · 2008 · 274 citations · Full text

Safety of factor VIII inhibitor bypass activity (FEIBA^®): 10‐year compilation of thrombotic adverse events

Hartmut J. Ehrlich, M. J. HENZL, Edward D. Gomperts · Haemophilia · 2002 · 220 citations

Mapping of binding sites for heparin, plasminogen activator inhibitor-1, and plasminogen to vitronectin's heparin-binding region reveals a novel vitronectin-dependent feedback mechanism for the control of plasmin formation.

Christine Kost, Werner Stüber, Hartmut J. Ehrlich et al. · Journal of Biological Chemistry · 1992 · 139 citations · Full text

Recombinant ADAMTS13 normalizes von Willebrand factor‐cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies

Barbara Plaimauer, Johanna A. Kremer Hovinga, Claudia Juno et al. · Journal of Thrombosis and Haemostasis · 2011 · 124 citations · Full text

Disease Mechanism, Autoantibody Production, Inhibitory Antibodies +6

Structural requirements for the extracellular interaction of plasminogen activator inhibitor 1 with endothelial cell matrix-associated vitronectin.

Klaus T. Preissner, J. Grulich‐Henn, Hartmut J. Ehrlich et al. · Journal of Biological Chemistry · 1990 · 118 citations · Full text